A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma

Overview

  • Study type

    Interventional
  • Study phase

    I/II
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

  • Site IRB
    • Scottsdale/Phoenix, Arizona: 15-007556
    • Jacksonville, Florida: 15-007556
    NCT ID: NCT02667886
    Sponsor Protocol Number: X4P-001-RCCA

About this study

The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in patients diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria

  • Has a histologically confirmed diagnosis of predominant clear cell (conventional) Renal Cell Carcinoma
  • Has received at least one prior course of treatment for ccRCC
  • Part C only
    • Prior treatment must include at least 1 course of VEGF-directed therapy
  • Has CT imaging done within 28 days of day 1 findings consistent with advanced ccRCC, including at least one extra-renal measurable target lesion meeting the criteria of RECIST version 1.1
  • Women of childbearing potential and men must agree to use effective contraceptive methods from screening, through the study, and for at least 4 weeks after the last dose of study drug
  • Women of childbearing potential must have a negative pregnancy test (serum or urine) on day 1 prior to initiating study treatment
  • Must be willing and able to comply with the protocol

Exclusion Criteria

  • Has life expectancy of less than 3 months
  • Has performance status Grade >2 (Eastern Cooperative Oncology Group [ECOG] criteria)
  • Has NYHA Class III or IV heart failure or uncontrolled hypertension (SBP ≥160 mm Hg; DBP ≥100 mm Hg)
  • Has previously received X4P-001
  • Parts A and B only
    • Has received a prior course of axitinib
    • Has received mTOR inhibitor(s) as their only prior treatment for ccRCC
  • Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except for ≤3 lesions treated by CyberKnife or excisional surgery, clinically stable for at least 4 weeks, and without evidence of recurrence on MRI imaging at screening
  • Has ongoing acute clinical adverse events NCI CTCAE Grade >1 resulting from prior cancer therapies (except alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction)
  • Has had within the past 6 months the occurrence or persistence of one or more of the following medical conditions that could not be controlled with usual medical care (e.g., required emergency care or hospitalization)
    • Hypertension
    • Angina
    • Congestive heart failure
    • Diabetes
    • Seizure disorder
  • Has had within the past 6 months the occurrence of one or more of the following events
    • Myocardial infarction
    • Cerebrovascular accident
    • Deep vein thrombosis
    • Pulmonary embolism
    • Hemorrhage (CTC Grade 3 or 4)
    • Chronic liver disease (meeting criteria for Child-Pugh Class B or C)
    • A second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ)
    • Organ transplantation
  • Has had within the 4 weeks prior to initiation of study drug, or is expected to have during the study period, surgery requiring general anesthesia
  • Has, at screening, serologic laboratory tests meeting one or more of the following criteria
    • An indeterminate or positive test for antibody to human immunodeficiency virus (HIV-1 or -2)
    • An indeterminate or positive test for antibody to hepatitis C virus (HCV), unless documented to have no detectable viral load on two independent samples
    • A positive test for hepatitis B surface antigen (HBsAg)
  • Has, at screening, safety laboratory tests meeting one or more of the following criteria
    • Hemoglobin <8.0 g/dL
    • Absolute neutrophil count (ANC) <1,500/μL
    • Platelets <75,000/μL
    • Creatinine >2.0x ULN
    • Serum aspartate transaminase (AST) >2.5x ULN
    • Serum alanine transaminase (ALT) >2.5x ULN
    • Total bilirubin >1.5x ULN (unless due to Gilbert's Syndrome)
    • International normalized ratio (INR) >1.5x ULN
  • Has received other anti-cancer therapy within the following specified intervals prior to Day 1
    • Tyrosine Kinase Inhibitor (TKI) within 2 weeks
    • Radiation therapy within 2 weeks
    • Bevacizumab within 4 weeks
    • Other chemotherapy (e.g., mitomycin-C, nitrosourea) or immunotherapy (e.g., antibody, cytokine) within 4 weeks
  • For investigational anti-cancer therapies, the interval will be determined in consultation with the Medical Monitor
  • Has, within 2 weeks prior to day 1, received a medication prohibited based on CYP3A4 interaction
  • Has, within 2 weeks prior to day 1, received systemic corticosteroids exceeding prednisone 10 mg per day or equivalent
    • For other immunosuppressive agents, the exclusionary dose and duration will be determined in consultation with the Medical Monitor
  • Is, within 2 weeks prior to day 1, nursing
  • Has, at the planned initiation of study drug, an uncontrolled infection
  • Has any other medical or personal condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Thai Ho, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Thai Ho, M.D., Ph.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

.
CLS-20193947

Mayo Clinic Footer